NCT06142188Not yet recruiting
Relmacabtagene Autoleucel in Hematologic Malignancies
A Real-world Study for the Treatment of Hematologic Malignancies With Relmacabtagene Autoleucel
Source: ClinicalTrials.gov · Last updated 21 Nov 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
To evaluate the efficacy and safety of Relmacabtagene Autoleucel in the treatment of adult patients with hematologic malignancies in real-world
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 150 (estimated)
- First submitted
- 15 Nov 2023
- Start date
- 28 Dec 2023
- Primary completion date
- 31 Dec 2038
- Lead sponsor
- Shanghai Ming Ju Biotechnology Co., Ltd.
- Diseases
- Follicular lymphoma
- NCT number
- NCT06142188
What you commit to
- Study type: Observational
- Planned participants: 150
- From 28 Dec 2023 to the primary completion date, 31 Dec 2038
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- 1.Patients who have been treated with Relma-cel and then have been treated with other CAR-T products.
Who the study is looking for
- Signed informed consent
- Patients who have been treated with Relma-cel, including those who have received off-label products;
- If previously enrolled in another clinical study, they must have completed follow-up in the previous study, or have withdrawn or lost follow-up in the previous study.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Beijing Cancer Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
| Peking University International Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.